Navigation Links
Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
Date:5/21/2009

hat chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatments. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. The Company was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board
2. Agendia Joins the Personalized Medicine Coalition (PMC)
3. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
4. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
5. Agendia BV Appoints Clinical and Scientific Advisory Board
6. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
7. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
8. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
9. Agendia Appoints New Chief Financial Officer
10. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
11. Agendia Appoints VP of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 29, 2015 According to a new ... by Application (Diagnostics, Therapeutics, R&D), by Technology (SELEX, Other Technologies), ... CRO) - Global Forecast to 2020", published by MarketsandMarkets, the ... 2020 from $107.56 Million in 2015, at a CAGR of ... and 67 F igures spread through 125 ...
(Date:6/29/2015)... Elsevier , a world-leading ... services, today announced the highlights of its journal Impact ... Citation Reports® (JCR) published by Thomson Reuters, Elsevier saw ... to 2014, ahead of the aggregate across other journals. ... 62 subject categories, up from 61 in 2013. ...
(Date:6/26/2015)... Lawrence, MA (PRWEB) , ... June 26, 2015 ... ... the U.S. Department of Agriculture (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) ... referred to as vomitoxin in feed and grains utilizing Charm’s ROSA DONQ-FAST5 Test. ...
(Date:6/26/2015)... June 23, 2015 ... addition of the "Global Cancer Biosimilars Market ... Market introduction of cancer biosimilar is required ... potential. Chemotherapeutic drugs have dominated the cancer segment ... been introduced in past few years. They are ...
Breaking Biology Technology:Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2Global Cancer Biosimilars Market Opportunity Outlook 2Global Cancer Biosimilars Market Opportunity Outlook 3
... Calif., Nov. 20 AMDL, Inc. (Amex:,ADL), ... China, through its,wholly owned subsidiary Jade Pharmaceutical ... in the development, manufacture and,marketing of proprietary ... has launched significant new expansion plans to ...
... into an old idea, MIT Institute Professor Mildred ... for controlling temperatures that could lead to substantial ... photovoltaic cells and electronic devices. , Novel ... consumer product: a simple, efficient way of cooling ...
... (Nasdaq: EXEL ) announced today that that it will hold ... a.m. ET /,7:00 a.m. PT to 2:00 p.m. ET / 11:00 ... and may be accessed in the Event Calendar,page under Investors at ... available until 9:00 p.m. PT / 12:00,a.m. ET on January 4, ...
Cached Biology Technology:AMDL Launches New JPGreen Business Strategy 2MIT: Thermoelectric materials are 1 key to energy savings 2MIT: Thermoelectric materials are 1 key to energy savings 3
(Date:6/17/2015)... JOSE, Calif. , June 17, 2015 /PRNewswire/ ... in human interface solutions, today announced that Xiaomi, ... adopted the Synaptics ® ClearPad ® ... of display driver integrated circuits (DDICs) for its ... Pro. By leveraging ClearPad for full in-cell display ...
(Date:6/16/2015)... 2015 Fingerprint Cards (FPC) raises the ... will amount to at least 340 MSEK to that it ... increase in market growth and orders received the revenue guidance ... revenue for 2015 will exceed 1,500 MSEK to an updated ... MSEK. Due to receipt of orders of touch ...
(Date:6/11/2015)... Va. , June 11, 2015 ... technology, announced today that its IdentityX Mobile Authentication ... (Fast IDentity Online) Alliance is an industry consortium ... open standards for simpler, stronger authentication.  In order ... must pass a rigorous series of tests that ...
Breaking Biology News(10 mins):Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... the UK have presented evidence that vigorous physical activity ... results were presented at the World Congress on Osteoporosis ... six-year olds participated in the study. Using advanced scanning ... structure of the femoral neck (hip) and thigh bone. ...
... Hinxton, 10 May 2010 The European Nucleotide Archive ... to become Europe,s primary access point to globally comprehensive ... available from the European Bioinformatics Institute (EMBL-EBI), a part ... DNA sequencing has led to previously unimaginable amounts of ...
... sources of renewable energy, but which ones should industry ... new study involving researchers from North Carolina State University ... burned. Their data and new computer models pave the ... maximize energy efficiency while minimizing environmental and human health ...
Cached Biology News:Enabling easy access to DNA sequence information 2Study paves way for new biofuels models, technologies 2
... Clone/PAD: ZMD.473. Immunogen: Synthetic peptide ... the mouse junctophilin-2. Specificity: Specific ... Mouse (positive controls: mouse skeletal muscle ... Applications: Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: ...
TGF-beta 2 MAb (Clone 8607)...
UCP1/2/3 (FL-307)...
ABIN-2 Polyclonal Ab 100 ug rabbit polyclonal antibody. Detects ABIN-2 in human/mouse. Tested in WB....
Biology Products: